Spnib 70mg (Dasatinib)

Description  of  Spnib 70mg (Dasatinib 70mg)

Spnib 70mg (Dasatinib 70mg) belongs to oral dual BCR/ABL and Src group of tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukaemia (CML). The main aim of Sprycel, are BCRABL, SRC, Ephrin’s and GFR.
Spnib 70mg (Dasatinib 70mg) is a prescription drug which used under the supervision of doctor.

INDICATIONS of  Spnib 70mg (Dasatinib 70mg)

Spnib 70mg (Dasatinib 70mg) is indicated for the treatment of adult patients having chronic myeloid leukaemia.
Spnib 70mg (Dasatinib 70mg) is indicated for the treatment of adult patients having acute lymphoblastic leukaemia

MECHANISM OF ACTION  of  Spnib 70mg (Dasatinib 70mg)

Dasatinib is a group of drug which belongs to protein tyrosine kinase inhibitor (TKI). Tyrosine kinases are proteins which work as chemical messengers to stimulate cancer cells to develop. Dasatinib inhibits the tyrosine kinases from passing chemical signals which tell the cells to develop.

Absorption of  Spnib 70mg (Dasatinib 70mg)

Not available

Distribution of  Spnib 70mg (Dasatinib 70mg)

volume of distribution 2505 L and plasma protein binding is 96%

Metabolism of  Spnib 70mg (Dasatinib 70mg)

Extensively metabolized in humans, mainly by the cytochrome P450 enzyme 3A4.

Excretion of  Spnib 70mg (Dasatinib 70mg)

Dasatinib excreted through the feces.
Half-life is 3-5 hours

 SIDE EFFECTS  of  Spnib 70mg (Dasatinib 70mg)

• Skin rash
  • Infection
  • Nausea
  • Dyspnea
  • Anorexia
  • Arthralgia
  • Asthenia
  • Constipation
  • Dizziness
  • Musculoskeletal pain
  • Anemia
  • Febrile neutropenia
  • Thrombocytopenia
  • Mucosal inflammation
  • Diarrhea
  • Headache
  • Haemorrhage
  • Fatigue
  • Pyrexia

PRECAUTIONS  of  Spnib 70mg (Dasatinib 70mg)

Using of Spnib 70mg (Dasatinib 70mg)  will results in Tumor lysis syndrome; maintain sufficient hydration and correct uric acid levels before to starting treatment
Spnib 70mg (Dasatinib 70mg)  will causes Risk of fluid retention and pleural/pericardial effusion; manage with supportive care measures and/or dose modification
Myelosuppression which involves severe thrombocytopenia, neutropenia and Anemia may occurs; may manage by dose interference, dose reduction, or blocking of treatment; hematopoietic growth factor has been used with resistant myelosuppression
Advise females of reproductive possible to do not become pregnancy, which may contains the use of effective contraceptive methods, during treatment with Spnib 70mg (Dasatinib 70mg)  and for 30 days after the final dose.
Certain patients with chronic phase CML and paediatric Ph+ ALL, reveals complete blood cell counts (CBCs) q2Weeks for 12 weeks, then q3Months thereafter, or as clinically indicated; show CBCs for the first 2 months weekly after that monthly,

DRUG INTERACTION of  Spnib 70mg (Dasatinib 70mg)

Spnib 70mg (Dasatinib 70mg) concomitant use with CYP3A4 inhibitors will increase Dasatinib plasma concentration.
Spnib 70mg (Dasatinib 70mg) combination with CYP3A4 inducers will reduces Dasatinib plasma concentration.
Spnib 70mg (Dasatinib 70mg) combination with antacids will decrease Dasatinib plasma concentration.
Spnib 70mg (Dasatinib 70mg) combination with H2 antagonists/proton pump inhibitors will decrease Dasatinib plasma concentration.
Spnib 70mg (Dasatinib 70mg) Interaction with CYP3A4 substrates will have their plasma concentration altered by Dasatinib.

PREGNANCY  of Spnib 70mg (Dasatinib 70mg)

Spnib 70mg (Dasatinib 70mg) will cause fetal harm while using during pregnancy. Advise a pregnant woman of the possible risk to a foetus.

LACTATION  of Spnib 70mg (Dasatinib 70mg)

Avoid breast feeding during Spnib 70mg (Dasatinib 70mg) treatment

DOSAGE of  Spnib 70mg (Dasatinib 70mg)

Chronic Myeloid Leukaemia :
Spnib 70mg (Dasatinib 70mg)  indicated for adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase and Used for treatment of chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with support or intolerance to before therapy contains imatinib
Newly diagnosed
Starting dose with 100 mg PO qDay (morning or evening).
May raised to 140 mg qDay if insufficient response.
Advanced CML:
Starting dose with 140 mg PO qDay
May increase to 180 mg qDay if insufficient reactions
Acute Lymphoblastic Leukaemia :
Sprycel indicated for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy
Initiate 140 mg PO qDay
May increase to 180 mg PO qDay if insufficient reactions.

STORAGE  of  Spnib 70mg (Dasatinib 70mg)

Store at 20℃ to 25℃. Keep away from the children Use the drug before expiry date Protect from direct sunlight. Discard the unused drug by asking the advice from doctor or pharmacist.

MISSED DOSE of  Spnib 70mg (Dasatinib 70mg)

In case of missed dose, patients must consult with medical oncologist and follow the regular dosing schedule